title: The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention?
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University College of Medicine, Columbus, OH, United States.
authors.forename: David E
authors.initials: DE
authors.lastname: Cohn
authors.affiliation: Park Nicollet Clinic, Medical Oncologist and Chief Medical Officer (Retired), Minneapolis, MN, United States.
authors.forename: William S
authors.initials: WS
authors.lastname: Shimp